While a number of U.S. Food and Drug Administration (FDA)-approved therapies exist for people with multiple sclerosis (MS), many more are in the pipeline. These experimental treatments for MS are in development stages that range from pre-clinical (studies in laboratory settings) to clinical, or studies that are tested in humans. Usually these start in healthy volunteers and then move onto patients.
These therapies aim, in general, to improve patients’ quality of life by slowing, halting or — ideally — reversing the damage that MS causes to the nervous system.
Read more about each of the experimental treatments for multiple sclerosis.
- ALKS 8700
- Ozanimod (RPC1063)
- Vatelizumab (GBR 500)
- Ibudolast (MN-166)
- Masitinib (AB1010)
- Tysabri (Natalizumab)
- Raxone (Idebenone)
- Siponimod (formerly BAF312)
Experimental treatments with potential for both types of MS
- Anti-LINGO-1 / BIIB033 / Opicinumab
- Laquinimod (Nerventra, ABR-215062)
- Lipoic acid
- Ocrelizumab (Ocrevus)
Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.